Abstract
The aim of the study was to evaluate the activity of decitabine, a hypomethylating agent, in the treatment of patients with chronic myelogenous leukemia (CML) in transformation. Thirty-seven patients with CML in blastic (20 patients) or accelerated phases (17 patients) were treated. Their median age was 52 years; 36 had Philadelphia chromosome-positive disease. Decitabine was given at 100 mg/m2 over 6 h every 12 h × 10 doses (1000 mg/m2) to 13 patients, and at 75 mg/m2 over 6 h every 12 h × 10 doses (750 mg/m2) to 24 patients. In blastic phase, two patients (10%) achieved a complete hematologic response (one with Ph suppression), and three (15%) had a hematologic improvement (marrow CR, platelets <100 × 103/μl), for an overall response rate of 25%. In accelerated phase, six patients (35%) returned to a second chronic phase (two with Ph suppression), one (6%) had a hematologic improvement, and two (12%) had a partial hematologic response, for an overall response rate of 53%. Prolonged myelosuppression was the most significant side-effect. The median time to recovery of granulocytes above 500 /μl was 48 days, and to recovery of platelets above 30 × 103/μl, 31 days. Febrile episodes occurred in 25 patients (68%) including documented infections in 17 patients (46%). Decitabine has promising activity in CML. The most significant side-effect is prolonged myelosuppression. Decitabine may show activity in other myeloid disorders such as acute myeloid leukemia and myelodysplastic syndrome, as well as in other hematologic malignancies, alone or with other drug combinations. Its value in the context of stem cell support should also be investigated.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kantarjian, H., O’Brien, S., Keating, M. et al. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. Leukemia 11, 1617–1620 (1997). https://doi.org/10.1038/sj.leu.2400796
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2400796
Keywords
This article is cited by
-
Management of chronic myeloid leukemia in 2023 – common ground and common sense
Blood Cancer Journal (2023)
-
Effects of 5′-azacytidine and alendronate on a hepatocellular carcinoma cell line: a proteomics perspective
Molecular and Cellular Biochemistry (2015)
-
Pharmacokinetic and pharmacodynamic analysis of 5-aza-2’-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy
Clinical Epigenetics (2013)
-
Inhibitors of DNA methylation: beyond myelodysplastic syndromes
Nature Clinical Practice Oncology (2005)